Archive

GLP-1 drugs linked to reduced risk of epilepsy

Written by Bruce Sylvester | 14 Dec 2025

A retrospective analysis of data from adults treated for type-2 diabetes indicates that glucose-lowering GLP-1 drugs could be linked to a lower risk of epilepsy. The findings appeared… read more.

Liraglutide could reduce monthly migraine days

Written by Bruce Sylvester | 24 Jun 2025

Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.

Weight-loss drugs cut alcohol intake by almost two-thirds, research in Ireland suggests

Written by Charlie King | 28 May 2025

Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four months, new research being presented at this year’s European Congress… read more.

First medical guideline recommends new prescription medications for weight loss

Written by Charlie King | 24 Oct 2022

Diet and exercise fail for most adults who try to lose weight in the long-term. Today the American Gastroenterological Association (AGA) released new evidence-based guidelines strongly recommending that these patients… read more.

Liraglutide prevents accumulation of lipid linked to cardiac mortality

Written by Charlie King | 14 Jun 2021

Researchers at the Karolinska Institutet, University of Oxford and University of Copenhagen have shown that elevated levels of lipids known as ceramides can be associated with a ten-fold… read more.